Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company that discovers and develops precision medicines, initially focused on oncology. Its proprietary Acrivon Predictive Precision Proteomics (AP3) platform measures drug-regulated protein signaling to guide drug discovery, patient… From the company’s description.
In fiscal 2025, Acrivon Therapeutics, Inc. reported a net loss of $77.91M. Operations used $63.66M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Acrivon Therapeutics, Inc. does
In the company’s own words
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company that discovers and develops precision medicines, initially focused on oncology. Its proprietary Acrivon Predictive Precision Proteomics (AP3) platform measures drug-regulated protein signaling to guide drug discovery, patient selection and clinical development, while its OncoSignature tests use tumor biopsies to identify patients predicted to respond to specific drug candidates. Acrivon’s pipeline includes ACR-368, a CHK1/2 inhibitor being studied in solid tumors including endometrial cancer; ACR-2316, a dual WEE1/PKMYT1 inhibitor in Phase 1 development; and ACR-6840, a preclinical CDK11 inhibitor. The company also operates a CLIA-certified laboratory to support clinical testing. Acrivon was founded in 2018 and in-licensed ACR-368 from Eli Lilly; its other named drug candidates are internally discovered. It reports its business as a single operating segment. Its website is www.acrivon.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1781174
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Acrivon Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Acrivon Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Acrivon Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Acrivon Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Acrivon Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”